Biomed-Lublin has a contract for the sale of Onko BCG products in Romania for a minimum of PLN 25 million

Biomed-Lublin has entered into an agreement with the pharmaceutical company Anisapharm for the registration, delivery and distribution of Onko BCG medicinal products in Romania, the company announced. The total minimum value of orders in the first 5 years of the agreement is to amount to EUR 5.25 million (approx. PLN 24.78 million).


Biomed-Lublin granted Anisapharm the right to sell and distribute Onko BCG 50 and 100 medicinal products in the territory of Romania, after prior registration. The total minimum value of orders in the first 5 years of the contract is to amount to EUR 5.25 million (PLN 24.78 million according to the exchange rate of the National Bank of Poland on February 6), with the binding minimum value of orders being 80% of the forecasted annual level of orders. In addition, it was agreed that the costs of registration and marketing will be borne by Anisapharm. The contract was concluded for 10 years (with the possibility of extension), and by the end of 2024, Anisapharm will register Onko BCG products in Romania. Commercialization is to take place in 2025, it was reported.

“The conclusion of the agreement with Anisapharm is in line with our Onko BCG product development strategy. I am pleased that the construction of the new production plant is proceeding according to plan, thanks to which our Onko BCG production capacity will be significantly increased, which in turn will allow us to meet the growing demand for these products on the global market. Entering another market will allow Biomed to further increase sales and diversify its sales channels. At the same time, we are working on other contracts and we do not forget about other products from our portfolio,” said the president of Biomed Lublin, Mieczysław Starkowicz, quoted in the release.

The company’s Onko BCG products are registered in Poland, Germany, Switzerland, Ukraine, Malta and Uzbekistan. Biomed Lublin also sells them to Croatia, Turkey, Uruguay, Lithuania, Greece, Great Britain and Spain.

(…)

Biomed-Lublin Wytwórnia Surowic i Szczepionek is a Polish pharmaceutical company operating since 1944. The company produces medicinal preparations (prescription drugs, medical devices and laboratory reagents used in biochemical and medical laboratories). The company has been listed on the main market of the Warsaw Stock Exchange since 2015.

Source

Our privacy policy